Quoin Pharma wins US notice of allowance for Netherton syndrome combination-treatment patent application

Quoin Pharmaceuticals. Ltd Sponsored ADR

Quoin Pharmaceuticals. Ltd Sponsored ADR

QNRX

0.00
  • Quoin Pharmaceuticals received a USPTO Notice of Allowance for U.S. patent application 18/428,570 covering combination treatment for Netherton Syndrome.
  • Claims cover treating Netherton Syndrome with topical serine protease inhibitor dipalmitoyl hydroxyproline plus an anti-inflammatory agent, including SPINK5 mutation patients.
  • Patent is expected to issue following payment of the USPTO issue fee, supporting IP protection for investigational QRX003 (QYLEKI).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.